Oncogenic mutations in BRAF drive constitutive kinase activity through single amino acid changes (notably the A-loop mutation V600E in melanoma), deletions within regulatory regions (e.g., β3–αC), or fusion to another protein such as the calcium-activated chloride channel TTYH3 (58, 59, 60, 61). Here, BRAF is linked to melanoma.